期刊文献+

HE4联合CA125检测对卵巢良恶性肿瘤的诊断价值 被引量:9

Values of human epididymis protein 4 combined with carbohydrate antigen 125 in diagnosis of human ovarian cancer and ovarian benign tumors
下载PDF
导出
摘要 目的探讨人附睾上皮分泌蛋白4(HE4)对卵巢癌的诊断意义及其与糖链抗原CA125联合检测对卵巢良、恶性肿瘤的诊断价值。方法检测22例卵巢癌患者、46例卵巢良性肿瘤患者及35例健康女性血清中的HE4和CA125水平。CA125的测定采用适用于96微孔反应板的时间分辨荧光测定仪测量,通过双抗体夹心时间分辨免疫荧光分析法进行测定。HE4的测定应用电化学发光法进行测定。结果卵巢癌组HE4水平明显高于卵巢良性肿瘤和健康对照组,差异均具有统计学意义(t_1=3.356,t_2=3.865,均P<0.05);卵巢癌组血清CA125水平也高于卵巢良性肿瘤组和健康对照组,差异均有统计学意义(t_1=4.656,t_2=5.126,均P<0.05)。单独检测HE4的灵敏度和特异度分别为77.27%和84.78%;单独检测CA125的灵敏度和特异度分别为90.91%和80.43%;二者联合检测时灵敏度和特异度分别为72.73%和89.13%。结论 HE4对卵巢癌的诊断有较高的特异度;CA125的特异度低于HE4;HE4对卵巢癌的诊断价值优于单独CA125检测;联合检测提高了特异度,降低了的灵敏度。 Objective To explore the diagnostic value of human epididymis protein 4 (HE4) in ovarian cancer and that of HE4 combined with carbohydrate antigen 125 ( CA125) in human ovarian cancer and ovarian benign tumors .Methods Serum levels of HE4 and CA125 in 22 cases of ovarian cancer , 46 cases of ovarian benign tumors and 35 cases of healthy controls were detected .Time-resolved fluorescence measurement apparatus applicable to 96 microporous reaction plate was used , and CA125 was measured by double antibody sandwich time-resolved immunofluorescence analysis method .Electrochemical luminescence method was used to determine HE 4.Results Serum levels of HE4 among ovarian cancer patients were obviously higher than those of ovarian benign tumors and healthy controls , and the difference was statistically significant (t1 =3.356,t2 =3.865, both P〈0.05).Serum levels of CA125 among ovarian cancer patients were obviously higher than those of ovarian benign tumors and healthy controls , and there was significant difference ( t1 =4.656,t2 =5.126, both P〈0.05).The sensitivity and specificity of HE4 was 77.27%and 84.78%, respectively, while the sensitivity and specificity of CA125 was 90.91%and 80.43%, respectively.The sensitivity and specificity of joint detection was 72.73%and 89.13%, respectively.Conclusion HE4 has high specificity in detecting ovarian cancer , which is higher than CA125.The diagnostic value of HE4 is superior to CA125 in detecting ovarian cancer .Joint detection improves specificity but reduces sensitivity .
出处 《中国妇幼健康研究》 2014年第2期273-275,共3页 Chinese Journal of Woman and Child Health Research
关键词 卵巢肿瘤 人附睾上皮分泌蛋白4 糖链抗原CA125 灵敏度 特异度 ovarian tumor sensitivity specificity
  • 相关文献

参考文献14

  • 1杨念念,严亚琼,龚洁,张思维,郑荣寿,陈万青.中国2003~2007年卵巢癌发病与死亡分析[J].中国肿瘤,2012,21(6):401-405. 被引量:61
  • 2Colombon,Van Gor P T,Parma G,et al.Ovarian cancer[J].Crit Rev Oncol Hemato1,2006,60(2):159-179.
  • 3孙静(综述),谢建华(审校).人附睾分泌蛋白与卵巢癌的关系[J].国际肿瘤学杂志,2010,37(3):222-225. 被引量:9
  • 4Galgano M T,Hampton G M,Frierson H F,et al.Comprehensive analysis of HE4 expression in normal and malignant human tissues [J].Mod Pathol,2006,19(6):847-853.
  • 5欧健,张晓霞,王翠翠,王丽娜.血清人附睾蛋白4的检测及其在卵巢癌诊断中的意义[J].吉林大学学报(医学版),2010,36(3):543-545. 被引量:21
  • 6Escudero J M,Auge J M,Filella X,et al.Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant disease[J].Clin Chem,2011,57(11):1534-1544.
  • 7胡晓舟,崔丽艳,张捷.健康人群血清HE4水平参考区间的初步探讨[J].中华检验医学杂志,2009,32(12):1376-1378. 被引量:27
  • 8Moore R G,Brown A K,Miller M C,et al.Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus [J].Gynecol Oncol,2008,110(2):196-201.
  • 9Anastasi E,Marchei G G,Viggiani V,et al.HE4:A new potential early biomarker for the recurrence of ovarian cancer[J].Tumor Biol,2010,31(2):113-119.
  • 10Havrilesky L J,Whitehead C M,Rubatt J M,et al.Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence[J].Gynecol Onco1,2008,110(3):374-382.

二级参考文献46

  • 1赵莹珺,杨剑峰,朱景德.人卵巢癌相关候选基因HE4(WFDC2)的转录调控主要由Sp1与位于-71和-48的Egr-1位点结合所介导[J].肿瘤,2004,24(6):517-525. 被引量:15
  • 2陈洁晶,吴英松,宁云山,董文其,李明.卵巢癌肿瘤标记物HE4基因的分子克隆与蛋白表达[J].热带医学杂志,2006,6(5):493-495. 被引量:10
  • 3苗青,孔北华.山东省上皮性卵巢癌发病因素分析——病例配对研究[J].癌症,2006,25(7):871-875. 被引量:8
  • 4Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors, 1991, 45 : 350- 357.
  • 5Wang K, Gan L, Jeffery E, et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene, 1999, 229 : 101-108.
  • 6Drapkin R, yon Homten HH, Lin Y, et al . Human epididymis protein 4 (HFA) is a secreted glycoprotcin that isoverexpressed by serous and endometrioid ovarian carcinomas. Cancer Res, 2005, 65:2162-2169.
  • 7Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res,2003, 63:3695-3700.
  • 8Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol,2008,108: 402-408.
  • 9Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Modem Path,2006, 19:847-853.
  • 10Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2) is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene, 2002, 21: 2768-2773.

共引文献148

同被引文献55

  • 1吴晓红.血清人附睾蛋白4、糖类抗原125检测联合卵巢恶性肿瘤风险评估指数对卵巢癌的诊断价分析[J].实用妇科内分泌电子杂志,2019,0(21):89-89. 被引量:1
  • 2Jing Lu,Xiao-Feng Li,Li-Xia Kong,Lin Ma,Su-Huan Liao,Chang-You Jiang.Expression and significance of cyclooxygenase-2 mRNA in benign and malignant ascites[J].World Journal of Gastroenterology,2013,19(40):6883-6887. 被引量:12
  • 3Lenhard M, Stieber P, Hertlein L, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses [J]. Clin Chem Lab Med: CCLM/FESCC, 2011,49 ( 21 ) : 2081-2088.
  • 4Lawicki S, Bedkowska G E, Gacuta-Szumarska E, et al. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors [J]. J Ovarian Res,2013,6( 1 ) :45.
  • 5Anastasi E, Granato T, Falzarano R, et al. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer[J]. J Ovarian Res ,2013, 6(1) :44.
  • 6Karolina P, Bjorg K J, Karin S, et al. Evaluation of ovarian cancer biomarkers HE4 and CA125 women presenting with a suspicious cystic ovarian mass [J]. Gynecol Onco1,2012,22 ( 4 ) :244-252.
  • 7Cristina A, Filomena M C, Elci I O, et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA)and risk malignancy index (RMI) for the classification of ovarian masses [J]. Clinics, 2012 67(5).437-441.
  • 8汪振文,高海彦,张会玲.血清HE4和CA125联合检测在卵巢肿瘤诊断中的价值[J].中国生育健康杂志,2014,20(7):481-482.
  • 9张海燕,孙红.Foxp3基因在卵巢癌中的研究进展[J].中国妇幼健康研究,2009,20(5):595-597. 被引量:2
  • 10苏彤,刘辉,任清霞,秦燕,徐风亮.HE4、TSGF和CA125联合检测诊断卵巢癌的价值[J].山东医药,2011,51(39):62-64. 被引量:13

引证文献9

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部